demonstrate that exosomes from CAFs transfer lncRNA CCAL to CRCs to activate Wnt/β‐catenin signaling pathway through HuR, leading to resistance to oxaliplatin and 5‐FU.[172] LINC00355 in exosomes from CAFs promotes cisplatin resistance of bladder cancer cells by regulating the miR‐34b‐5p/ABCB1 axis.[173] Exosomes from ESCC cells transfer lncRNA POU3F3 to normal fibroblasts to induce their conversion to CAFs, which in turn promotes cisplatin resistance of ESCC cells by secreting interleukin 6 (IL‐6).[174]. This evidence concerns the gene IL6 and urinary bladder cancer.